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Available online 22 April 2017We report the generation-characterization of a fetal liver (FL) B-cell progenitor (BCP)-derived human induced
pluripotent stem cell (hiPSC) line CRISPR/Cas9-edited to carry/express a single copy of doxycycline-inducible
Cas9 gene in the “safe locus” AAVS1 (iCas9-FL-BCP-hiPSC). Gene-edited iPSCs remained pluripotent after
CRISPR/Cas9 genome-edition. Correct genomic integration of a unique copy of Cas9 was conﬁrmed by PCR and
Southern blot. Cas9 was robustly and speciﬁcally expressed on doxycycline exposure. T7-endonuclease assay
demonstrated that iCas9 induces robust gene-edition when gRNAs against hematopoietic transcription factors
were tested. This iCas9-FL-BCP-hiPSCwill facilitate gene-editing approaches for studies on developmental biolo-
gy, drug screening and disease modeling.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).G
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rigin human
dditional origin info Age: 19–22 weeks of human fetal development
Sex: XX
ell source Fetal liver B-cell progenitors
ethod of reprogramming Non-integrative (Sendai virus)
ssociated disease Non applicable
ene/locus Cas9 inserted in AAVS1 locus
ethod of modiﬁcation CRISPR-Cas9Leukemia Research Institute,
y of Barcelona, Barcelona, Spain.
s Leukemia Research Institute,
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ame of transgene or resistance Cas9
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ate archived/stock date December 2016
ell line repository/bank
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Institutional Review Board approval
obtained (CMRB-CEIC-26/2013)Resource utility
This iCas9-FL-BCP-iPSC constitutes a unique tool facilitating the
screening on multiple sgRNAs (and libraries) for the generation of
locus-speciﬁc genetic-edited (knock-in, knock-out, codon substitution,
structural rearrangements, etc.) hiPSC for developmental biology, com-
pound screening and disease modeling.
Resource details
Fresh fetal liver (FL) was collected from developing human embryos
aborted at 19–22 weeks of pregnancy. Human tissue was provided by
The Vrelinghuis abortion clinic (Utrecht, The Netherlands) upon signedivecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. CRISPR/Cas9-mediated generation of iCas9-FL-BCP-hiPSCs by gene targeting at the AAVS1 locus.
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139J. Castaño et al. / Stem Cell Research 21 (2017) 137–140informed consent and approval by our local Ethics and Biozahard Board
Committees (CMRB-CEIC-26/2013) through a formal collaborationwith
the Erasmus-Medical Centre, Rotterdam, The Netherlands). Mononuclear
cells (MNCs) were isolated using Ficoll-Hypaque and CD34+ CD19+ B-
cell progenitors (BCP) were FACS-puriﬁed and reprogrammed by infec-
tion with non-integrative tetracistronic SeV vectors encoding the tran-
scription factors OCT4, SOX2, KLF4, and MYC (OSKM) (Muñoz-López et
al., 2016a; Muñoz-López et al., 2016b). Resulting FL CD34 + CD19 +
− iPSC lines (FL-BCP-hiPSC) were established as previously reported
(Muñoz-López et al., 2016a; Muñoz-López et al., 2016b; Bueno et al.,
2016). This FL-BCP-hiPSC was genome-edited to harbor the Cas9 coding
sequence controlled by a doxycycline-inducible cassette in the genomic
“safe harbor” AAVS1 (iCas9-FL-BCP-hiPSC). A single cassette containing
both the rTetR activator under CAG promoter and the Tetracycline Re-
sponse Element (TRE) promoter driving the expression of Cas9, was
inserted in the AAVS1 locus by homologous recombination using the
Cas9 nuclease and a guide RNA (gRNA) sequence (Mali et al., 2013)
against intron 1 of AAVS1 locus (Fig. 1 panel A). The Fig. 1 panel A
shows a schematic representation of the donor vector used for insertion
of the iCas9 cassette into the AAVS1 locus (HA, homology arm; puro, pu-
romycin; SA, splice acceptor; T2A, self-cleaving 2A peptide; CAG, CMV
early enhancer/chicken β actin promoter. rTetR, reverse Tet repressor;
pA, poly A signal; TRE, Tet response element). Correct genomic integra-
tion of a unique copy of Cas9 was conﬁrmed by both genomic PCR (not
shown) and Southern blot analysis (Fig. 1 panel B) in several iPSC clones,
using a 5′-internal probe (left panel) and a 3′-external probe (right
panel). Red asterisks indicate clones with the desired targeted insertions
of the iCas9. Three iCas9-FL-BCP-hiPSC cloneswere induced for 72 hwith
2 μg/ml of doxycycline and analyzed for Cas9 expression by qPCR (Fig. 1
panel C), showing a robust, non-leaky expression of Cas9. To functionally
validate the Cas9 expression, iCas9-FL-BCP-hiPSCs were nucleofected
with different gRNAs against three hematopoietic transcription factors
(MLL, GATA2 and AF4) in presence/absence of doxycycline. The T7 endo-
nuclease I assay conﬁrmed a high percentage (25%–62%) of cleavage
(Fig. 1 panel D). Red asterisks depict the expected T7EI-speciﬁc fragments
used to quantify indel frequency. The in silico-predicted (crispr.mit.edu)
top off-targets of AAVS1 gRNA (RNF4, RHOT2, FAIM2, RPL8, BTNL8,
MYBL2) were sequence-veriﬁed in iCas9-FL-BCP-hiPSCs and they were
consistently found unaltered, demonstrating the high speciﬁcity of the
approach used (data not shown).
Importantly, iPSCs remained pluripotent after CRISPR/Cas9 gene
editing. iCas9-FL-BCP-hiPSCs retained hESC-like morphology and
expressed the pluripotency markers alkaline phosphatase (AP) (Fig. 1
panel E), OCT4, NANOG, SOX2, REX1, CRIPTO, and DNMT3B (Fig. 1 panel
F). Endogenous expression of NANOG and OCT4 was accompanied by
the extensive loss of CpG methylation in their promoters (Fig. 1 panel
G). By ﬂow cytometry, gene-edited iPSCs consistently expressed SSEA-
3, SSEA-4, TRA-1-60, and TRA-1-81 (Fig. 1 panel H). In vivo, theTable 1
Summary of quality control testing and results for iCas9-FL-BCP-hiPSC.
Classiﬁcation Test Result
Morphology Photography hESC-l
AP staining Positiv
Phenotype qPCR Expres
SOX2,
Promoter demethylation loss of
Flow cytometry SSEA-3
and TR
Genotype Karyotype 47 (XX
Resolu
Identity VDJH (BCR) rearrangement Incom
Mutation analysis Southern blot One sp
Microbiology and virology Mycoplasma Mycop
Differentiation potential Teratoma formation Repres
Donor screening N/A
Genotype additional info N/Adifferentiation capacity was conﬁrmed by teratoma formation in NSG
mice comprising tissue representing all three germ layers (Fig. 1
panel I).
Materials and methods
iPSC generation, maintenance and characterization
iPSCs were generated using OKSM polycistronic SeV vector
(Muñoz-López et al., 2016a; Muñoz-López et al., 2016b) and were fully
characterized before and after gene edition as previously described
(Bueno et al., 2016).
Promoter demethylation
Bisulﬁte pyrosequencing ofOCT4 andNANOGpromoterswasdone as
described (Bueno et al., 2016).
Immunophenotyping
Antibodies used to check by ﬂow cytometry the pluripotency-
associated markers are detailed in Table 2.
CRISPR/Cas9-edition of hiPSCs expressing a doxycycline-inducible Cas9
TheCAG-rTetR cassettewas PCR ampliﬁed fromAAVS1-Neo-M2rtTA
(Addgene #60843)with primers containing restriction sites for SalI and
ClaI. After ampliﬁcation and enzyme-digestion, the CAG-rTetR cassette
was cloned in the Puro-Cas9 donor vector (Addgene #58409). Finally,
a gBlock fragment (IDT Technologies) designed with two opposite
poly-A sequences was cloned using MluI and ClaI enzymes. A gRNA se-
quence targeting the AAVS1 intron 1 (5′-GGGGCCACTAGGGACAGGAT-
3′) was in vitro transcribed (IVT). To edit the iPSCs, 200.000 cells were
electroporatedwith 100 pmol Cas9 nuclease (IDT - Integrated DNA Tech-
nologies), 120 pmol the IVT-gRNA against AAVS1 intron 1, and 5 μg of
linearized donor vector. Electroporation was performed using Neon
Transfection System (ThermoFisher) at 1400 V, 5 ms and 3 pulses in a
100 μl tip. Cells were then selected with 1 μg/ml puromycin.
Southern blot
Genomic DNA from each cell line was isolated with Maxwell® RSC
Cultured Cells DNA Kit (Promega). 6 μg of DNA from each clone was
digested with SphI (for 5′ probe) or BglII (for 3′ probe) (New England
Biolabs), separated on a 1% agarose gel and transferred to a nylon
membrane (RPN303B, Amersham). Membranes were hybridized with
DIG-dUTP labeled probes. Probes were detected by an AP-conjugated
DIG-Antibody (Roche Diagnostics) using CDP-Star (Sigma-Aldrich) asData
ike morphology Fig. 1 panel E top
e Fig. 1 panel E bottom
sion of pluripotency markers: OCT4, NANOG,
CRIPTO, REX, DNMT3B
Fig. 1 panel F
CpG methylation in OCT4 and NANOG promoters Fig. 1 panel G
(76%), SSEA-4 (100%), TRA-1-60 (100%)
A-1-81 (99%)
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) + 20
tion: 400-band level
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Table 2
Antibodies and primers used in this study.
Antibodies used for immunocytochemistry/ﬂow-citometry
Antibody Dilution Company Cat # and RRID
SSEA-3-PE Rat anti-SSEA-3 1:100 BD Bioscience Cat#560237, RRID:AB_1645542
SSEA-4-v450 Mouse anti-SSEA-4 1:100 BD Bioscience Cat#561156, RRID:AB_10896140
TRA-1-60-BV510 Mouse anti-TRA-1-60 1:100 BD Bioscience Cat#563188, RRID:AB_2637036
TRA-1-81-AlexaFlour647® Mouse anti-TRA-1-81 1:100 BD Bioscience Cat#560793, RRID:AB_10550550
Primers
Target Forward/Reverse primer (5′–3′)
Genomic PCR 5′ junction CTGCCGTCTCTCTCCTGAGT/GTGGGCTTGTACTCGGTCAT
3′ junction GGCGATCTGACGGTTCACTAAAC/GAATCCACCCAAAAGGCAGC
Southern blot 5′ probe AGGTTCCGTCTTCCTCCACT/GTCCAGGCAAAGAAAGCAAG
3′ probe ACAGGTACCATGTGGGGTTC/CTTGCCTCACCTGGCGATAT
T7 assay MLL CAGCACTCTCTCCAATGGCA/TAAGCCTCCCATCTCCCACA
AF4 GGGGAAAAAAAACATTTCGGCGACATG/CTACCATTTCCCTCATTCCAATTCACTCC
GATA2 CGTGTCGCTGGGATCAAG/TCCCCAAAGAAAGCCAGAAAC
RNA in vitro transcription AAVS1 IVT GAAATTAATACGACTCACTATAGGGGGCCACTAGGGACAGGATGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC
MLL IVT GAAATTAATACGACTCACTATAGTTAGCAGGTGGGTTTAGCGCGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC
AF4 IVT GAAATTAATACGACTCACTATAGGTCTCATTCCAGCAACACGTGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC
GATA2 IVT CATGTAGTTGTGCGCCGTTTTAGAGCTAGA/AAAAGCACCGACTCGGTGCC
Pluripotency Markers (qPCR) OCT4 GGGTTTTTGGGATTAAGTTCTTCA/GCCCCCACCCTTTGTGTT
NANOG ACAACTGGCCGAAGAATAGCA/GGTTCCCAGTCGGGTTCAC
SOX2 CAAAAATGGCCATGCAGGTT/AGTTGGGATCGAACAAAAGCTATT
REX1 CCTGCAGGCGGAAATAGAAC/GCACACATAGCCATCACATAAGG
CRIPTO CGGAACTGTGAGCACGATGT/GGGCAGCCAGGTGTCATG
DNMT3B GCTCACAGGGCCCGATACTT/GCAGTCCTGCAGCTCGAGTTTA
Housekeeping gene GAPDH GCACCGTCAAGGCTGAGAAC/AGGGATCTCGCTCCTGGAA
Off-target genomic PCR RNF4 CAGACCGTGACTCCCGAAA/GTCAGCGGGGAACAAAAACC
RHOT2 TGTTACTGGGCGAGGGTAGG/CTACGGCCGCTACCTGAGTA
FAIM2 AGGCTCGTCCCATCCTTTTG/CACATCCCCATTTGCTCCCT
RPL8 GCAGGCAGTTCTAGAAGCCA/CCTTAGTTATCTGGATTTCCAGAAC
BTNL8 TAGGAGTCTTGGTGGTGTTCAT/ATATCGTGGCACCTGGCTAC
MYBL2 GCAGTCGGAGGAAGTGACAA/CTCCTGGCCCCTCTTAGACT
Mycoplasma PCR Nature TGCACCATCTGTCACTCTGTTAACCTC/GGGAGCAAACAGGATTAGATACCCT
M1 ACACCATGGGAGCTGGTAAT/CTTCATCGACTTTCAGACCCAAGGCAT
140 J. Castaño et al. / Stem Cell Research 21 (2017) 137–140a substrate for chemiluminescence. Probes were synthesized by PCR
using the PCR DIG Probe Synthesis Kit (Roche Diagnostics). 5′ probe
was generated using plasmidic DNA and 3′ probe using genomic DNA
as a templates. Primers used for probes are detailed in Table 2.T7 endonuclease assay
iCas9-FL-BCP-hiPSCswere treatedwith doxycycline (2 μg/ml) for two
days before and during transfection. Cells were dissociatedwith Accutase
(Stem Cell Technologies) and 200.000 cells were electroporated with
120 pmol of a single IVT-gRNA (MLL, GATA2 or AF4). Genomic DNA was
extracted four days after gRNA transfection. Genomic regions ﬂanking
the CRISPR target sites were PCR ampliﬁed (Table 1). PCRs were dena-
tured and re-annealed and then PCRs were treated with 5U of T7EI at
37 °C for 1 h.In vitro transcription
T7 RNA polymerase promoter was added to gRNA sequences by PCR
using as a template the pSpCas9(BB)-2A-GFP (PX458) plasmid (Addgene
#48138) containing the guide RNA sequences forMLL, GATA2 or AF4. PCR
ampliﬁcation were performed using speciﬁc forward primers and a uni-
versal reverse primer (Table 2). PCR products were used as templates
for IVT using the HiScribe™ T7 High Yield RNA Synthesis Kit (New
England Biolabs). The resulting gRNAswere puriﬁed using theMEGAclear
kit (Life Technologies), eluted in RNase-free water and stored at−80 °C
until use.Mycoplasma test
Primers used are listed in Table 2. PCR conditions were:
94 °C: 20″
×40 cycles
94ªC: 20″
55 °C: 20″ (Nature primer) or 58 °C: 10″ (M1 primer)
65ªC: 20–40″
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.04.011.
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